Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE)

Background and purpose: The novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), now named coronavirus disease 2019 (COVID-19), may change the risk of stroke through an enhanced systemic inflammatory response, hypercoagulable state, and endothelial damage in the cerebrovascular system. Moreover, due to the current pandemic, some countries have prioritized health resources towards COVID-19 management, making it more challenging to appropriately care for other potentially disabling and fatal diseases such as stroke. The aim of this study is to identify and describe changes in stroke epidemiological trends before, during, and after the COVID-19 pandemic. Methods: This is an international, multicenter, hospital-based study on stroke incidence and outcomes during the COVID-19 pandemic. We will describe patterns in stroke management, stroke hospitalization rate, and stroke severity, subtype (ischemic/hemorrhagic), and outcomes (including in-hospital mortality) in 2020 during COVID-19 pandemic, comparing them with the corresponding data from 2018 and 2019, and subsequently 2021. We will also use an interrupted time series (ITS) analysis to assess the change in stroke hospitalization rates before, during, and after COVID-19, in each participating center. Conclusion: The proposed study will potentially enable us to better understand the changes in stroke care protocols, differential hospitalization rate, and severity of stroke, as it pertains to the COVID-19 pandemic. Ultimately, this will help guide clinical-based policies surrounding COVID-19 and other similar global pandemics to ensure that management of cerebrovascular comorbidity is appropriately prioritized during the global crisis. It will also guide public health guidelines for at-risk populations to reduce risks of complications from such comorbidities. © 202

Potential role of KDAF in regulation of airway remodeling in asthma

Subepithelial fibrosis is a major feature of airway remodeling in asthma characterized by increased deposition of collagen and decreased ability of fibroblasts to produce collagenase. Our group has recently identified a family of proteins, keratinocyte anti-fibrogenic factor (KDAF) that induce collagenase expression in dermal fibroblasts. We examined the ability of lung epithelial cells to release KDAF and assessed its effect on collagenase production from fibroblasts, in vitro. We also studied antifibrotic effects of KDAF in the presence of transforming growth factor-β 1(TGF-β 1), a known contributor to the development of peribronchiolar fibrosis in asthma. A549 and HS24 cell lines were incubated with low FBS concentration medium for 24 h. The epithelial conditioned medium (CM) was subjected to Western blot analysis to detect KDAF. MMP-1 and type I collagen mRNA expression was examined by Northern blot analysis following treatment (24 hr) with CM and recombinant KDAF (2.5μg/ml). The effect of TGF-β 1(150 pg/ml) on production of MMP-1 was examined in the presence and absence of recombinant KDAF (2.5 μg/ml) and CM. A549 and HS24 epithelial cells released measurable KDAF the latter increased MMP-1 expression and decreased type I collagen production in fetal fibroblasts. Upregulation of MMP-1 expression in fibroblasts was sustained following treatment with TGF-β 1 in the presence of CM and recombinant KDAF. Lung epithelial cell-derived KDAF appears to have potent antifibrotic effects. We postulate that reduction of KDAF in asthmatic airways may contribute to the development of profibrotic events leading to airway remodeling

Therapeutic management of acute intracerebral haemorrhage

Intracerebral haemorrhage (ICH) is a stroke resulting from spontaneous rupture of an intracranial vessel and is associated with high early mortality and long-term morbidity rates. With the exception of dedicated stroke units or neurocritical care, no surgical or medical intervention has been proven to effectively improve outcome following ICH. Pharmacotherapeutic considerations include optimal blood pressure control and the choice of antihypertensive agents. Acute haematoma expansion represents the most obvious acute treatment target. The use of haemostatic agents may have a role in ICH management; although it appears improved patient selection may be required before the use of these agents can be demonstrated clinically. In patients with anticoagulant-associated ICH, a number of therapeutic agents may be used to urgently reverse the coagulopathy, although further clinical trials are required. Recurrent bleeding and future thrombo-embolic event rates in patients who require anticoagulation following ICH risks are difficult to determine accurately, although risk stratification data are emerging. This article reviews the pathophysiology, natural history and the evidence supporting present therapeutic management practices for ICH. The authors' practice based on best available evidence is provided

Spontaneous limb movements and posturing secondary to acute basilar artery occlusion: a potentially devastating seizure mimic

Basilar artery occlusion is a devastating but treatable form of ischaemic stroke with high morbidity and mortality rates. The diagnosis is often challenging due to considerable heterogeneity of clinical signs and symptoms. We report a case of an acute basilar artery occlusion presenting with decreased level of consciousness associated with rhythmic tonic movements of the four extremities, mimicking seizure activity. The patient was treated with intravenous thrombolysis and subsequently gained good recovery. Awareness of this entity is required to recognise this potentially treatable, but otherwise devastating seizure mimic

DWI Reversal Is Associated with Small Infarct Volume in Patients with TIA and Minor Stroke

The implications of the reversal of DWI abnormalities in patients with TIA and minor strokes were assessed. Patients were imaged within 24 hours of symptoms and followed for 3 months and baseline and final infarct volumes were calculated using DWI and FLAIR, respectively. Over 55% of patients had DWI lesions and 37% had perfusion deficits. DWI reversal occurred in 6% of patients with lesion volume being considerably smaller than in those that did not reverse. Perfusion abnormalities were less common in reversible lesions as well. The authors concluded that DWI lesion reversal is uncommon and more likely with smaller lesions